In September 2014 BMC conducted a detailed market and technology analysis (a kind of an “IN DEPTH” type of analysis) for a one of the OncoArendi Therapeutics’ technologies. Results of the work constituted a basis for the market part of the STRATEGMED application in the National Research and Development competition. The application was positively evaluated and recommended for financing in the amount of app. 6,5 M EUR. The application was ranked 2nd out of 109 evaluated applications. Congratulations!